232 related articles for article (PubMed ID: 36189576)
1. IL-4 receptor blockade is a global repressor of naïve B cell development and responses in a dupilumab-treated patient.
Mountz JD; Gao M; Ponder DM; Liu S; Sun CW; Alduraibi F; Sullivan K; Pat B; Dell'Italia LJ; Hsu HC
Clin Immunol; 2022 Nov; 244():109130. PubMed ID: 36189576
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of human IL-4 receptor subunits shows compartmentalization in steady state and dupilumab treatment.
Heeb LEM; Boyman O
Allergy; 2023 Apr; 78(4):1073-1087. PubMed ID: 36334079
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
[TBL] [Abstract][Full Text] [Related]
4. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis.
Bakker DS; van der Wal MM; Heeb LEM; Giovannone B; Asamoah M; Delemarre EM; Drylewicz J; Nierkens S; Boyman O; de Bruin-Weller MS; Thijs JL; van Wijk F
J Invest Dermatol; 2021 Aug; 141(8):1943-1953.e13. PubMed ID: 33610558
[TBL] [Abstract][Full Text] [Related]
5. IL-13 antagonists in the treatment of atopic dermatitis.
Tubau C; Puig L
Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab: Basic aspects and applications to allergic diseases.
Matsunaga K; Katoh N; Fujieda S; Izuhara K; Oishi K
Allergol Int; 2020 Apr; 69(2):187-196. PubMed ID: 32007360
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab for the treatment of asthma.
Pelaia C; Vatrella A; Gallelli L; Terracciano R; Navalesi P; Maselli R; Pelaia G
Expert Opin Biol Ther; 2017 Dec; 17(12):1565-1572. PubMed ID: 28990423
[TBL] [Abstract][Full Text] [Related]
8. IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases.
Aranda CJ; Gonzalez-Kozlova E; Saunders SP; Fernandes-Braga W; Ota M; Narayanan S; He JS; Del Duca E; Swaroop B; Gnjatic S; Shattner G; Reibman J; Soter NA; Guttman-Yassky E; Curotto de Lafaille MA
Allergy; 2023 Mar; 78(3):752-766. PubMed ID: 36445014
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Kraft M; Worm M
Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
[TBL] [Abstract][Full Text] [Related]
10. Drug evaluation review: dupilumab in atopic dermatitis.
Hamilton JD; Ungar B; Guttman-Yassky E
Immunotherapy; 2015; 7(10):1043-58. PubMed ID: 26598956
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
12. A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated With Pulmonary Tuberculosis: A Case Report and the RNA-seq Analysis.
Chen S; Zhan S; Hua C; Tang Y; Cheng H
Front Immunol; 2022; 13():825796. PubMed ID: 35222408
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab for the Treatment of Atopic Dermatitis.
Ferreira S; Torres T
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.
Ungar B; Glickman JW; Golant AK; Dubin C; Marushchak O; Gontzes A; Mikhaylov D; Singer GK; Baum D; Wei N; Sanin A; Gruenstein D; Lebwohl MG; Pavel AB; Guttman-Yassky E
J Allergy Clin Immunol Pract; 2022 Jan; 10(1):134-142. PubMed ID: 34737108
[TBL] [Abstract][Full Text] [Related]
15. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis.
Callewaert C; Nakatsuji T; Knight R; Kosciolek T; Vrbanac A; Kotol P; Ardeleanu M; Hultsch T; Guttman-Yassky E; Bissonnette R; Silverberg JI; Krueger J; Menter A; Graham NMH; Pirozzi G; Hamilton JD; Gallo RL
J Invest Dermatol; 2020 Jan; 140(1):191-202.e7. PubMed ID: 31252032
[TBL] [Abstract][Full Text] [Related]
16. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis.
Nakazaki K; Yoshida M; Masamoto Y; Shinozaki-Ushiku A; Ikemura M; Hisamoto T; Yasunaga M; Sato S; Kurokawa M
Int J Hematol; 2022 Sep; 116(3):446-452. PubMed ID: 35355217
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab for the treatment of adolescents with atopic dermatitis.
Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
[TBL] [Abstract][Full Text] [Related]
18. Rosacea associated with dupilumab therapy.
Heibel HD; Hendricks AJ; Foshee JP; Shi VY
J Dermatolog Treat; 2021 Feb; 32(1):114-116. PubMed ID: 31132923
[No Abstract] [Full Text] [Related]
19. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
Blauvelt A; Simpson EL; Tyring SK; Purcell LA; Shumel B; Petro CD; Akinlade B; Gadkari A; Eckert L; Graham NMH; Pirozzi G; Evans R
J Am Acad Dermatol; 2019 Jan; 80(1):158-167.e1. PubMed ID: 30092324
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL-4/IL-13 for the treatment of asthma: the story so far.
Moran A; Pavord ID
Expert Opin Biol Ther; 2020 Mar; 20(3):283-294. PubMed ID: 31914819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
